One-year choroidal thickness changes after photodynamic therapy for central serous chorioretinopathy evaluated by widefield optical coherence tomography

Graefes Arch Clin Exp Ophthalmol. 2024 Dec;262(12):3805-3814. doi: 10.1007/s00417-024-06578-8. Epub 2024 Jul 12.

Abstract

Purpose: To evaluate the changes in choroidal thickness 1 year after half-dose photodynamic therapy (PDT) for central serous chorioretinopathy (CSC) using widefield swept-source optical coherence tomography.

Methods: We retrospectively reviewed 21 patients with CSC who unilaterally underwent half-dose PDT and completed a 12-month follow-up. Choroidal thickness was evaluated before and after PDT within an 18-mm circular grid centered on the fovea subdivided into nine areas in the treated and untreated fellow eyes.

Results: All 21 treated eyes showed complete resolution of subretinal fluid at 3 months after PDT, without any recurrence at 12 months. The mean choroidal thickness in all nine areas significantly decreased after PDT at 3 months (P < 0.05) and remained unchanged at 12 months (P < 0.05) compared with that at baseline. However, the subtracted choroidal thickness maps between 3 and 12 months detected significant variations among the cases, classified into an enhanced pattern in 10 eyes (47.6%), an attenuated pattern in six eyes (28.6%), and a stable pattern in five eyes (23.8%). The 21 untreated fellow eyes also showed a decrease in mean choroidal thickness in three of the nine subdivided areas at 12 months (P < 0.05), but this decrease was limited posteriorly.

Conclusion: The reduction in mean choroidal thickness after half-dose PDT for CSC was extensively maintained for 1 year. However, subclinical hemodynamic changes in the entire choroid occurred longitudinally even in the absence of disease recurrence.

Keywords: Central serous chorioretinopathy; Choroid; Pachychoroid; Photodynamic therapy; Vortex vein; Widefield optical coherence tomography.

MeSH terms

  • Adult
  • Aged
  • Central Serous Chorioretinopathy* / diagnosis
  • Central Serous Chorioretinopathy* / drug therapy
  • Central Serous Chorioretinopathy* / physiopathology
  • Choroid* / diagnostic imaging
  • Choroid* / pathology
  • Female
  • Fluorescein Angiography* / methods
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Male
  • Middle Aged
  • Patient Acuity
  • Photochemotherapy* / methods
  • Photosensitizing Agents* / therapeutic use
  • Retrospective Studies
  • Time Factors
  • Tomography, Optical Coherence* / methods
  • Treatment Outcome
  • Verteporfin* / therapeutic use
  • Visual Acuity*

Substances

  • Photosensitizing Agents
  • Verteporfin